Biotech Giant Bets $8 Billion on Breakthrough Cancer Drug

Markets are buzzing as the week gets underway with major acquisitions and a notable UK name eyeing US exposure with a NYSE listing. In the mix, a major biotech bet has caught investors’ attention with its blockbuster potential. Here’s what you need to know.

On Behalf of The FUTR Corp.

Every tech cycle has its turning point.

The moment a breakthrough goes from hype to everyday life.

In smartphones, it was the iPhone.

In EVs, it was Tesla.

In streaming, it was Netflix.

Now the same setup is happening in AI.

The first wave was chatbots. But the real wealth could come from AI Agents.

Agents that scan contracts, trigger payments, and deliver offers in real time.

And this tiny stock is first in line:

This isn’t vaporware. The rails are already proven:

Zero-party data is becoming the new oil.  It’s structured, verified, and licensed directly by consumers. With their new payment platform and a Utility Token fueling every exchange, this model could turn the data economy into a perpetual revenue machine.

The big trigger? A Q3 2025 consumer launch that could put it on the radar overnight.

Don’t wait until CNBC is hyping it.

Get the name and stock symbol here before the crowd.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Markets are edging higher despite the risk of a government shutdown as early as Wednesday.

Nasdaq Futures: $24,877.25 (+0.61%)

S&P Futures: $6,730.25 (+0.50%)

Dow Futures: $46,754.00 (+0.43%)

10-Year: 4.143% (-0.044%)

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings:

Economic Reports:

AstraZeneca (NYSE: AZN.L) is pursuing a listing on the New York Stock Exchange as it targets a front-and-center position with US investors. 

Nearly half of AstraZeneca's sales already come from the US, with the drug giant targeting a 50% increase by 2030. A direct NYSE listing makes it easier for American investors to buy in without dealing with the quirks of ADRs.

Of course, there’s a political subplot, too. Washington's been leaning on big pharma to put more skin in the game at home. AstraZeneca is playing ball, promising to pump $50 billion into US R&D and manufacturing. It's part charm offensive, part insurance policy against tariffs and price-cutting threats.

My Take For You: The switch from ADRs to a direct NYSE listing is less about corporate drama and more about access. 

My Verdict: This is a positioning play, not a panic move. AstraZeneca is making itself more investable to US funds while keeping its UK roots intact. For long-term holders, nothing breaks here. For potential buyers, the key watchpoints are US sales momentum, margins, and the extent to which trading volume migrates stateside. Smart strategy overall, but the benefits show up over years, not weeks.

Genmab is going shopping, and it's not for coffee pods. The Danish biotech company has just signed an $8 billion all-cash deal to acquire Merus, paying $97 per share. The crown jewel here is petosemtamab, Merus's late-stage antibody drug that has been catching regulators' attention with not one, but two FDA Breakthrough Therapy designations for head and neck cancer.

The drug is already in two Phase 3 trials, and if all goes to plan, Genmab could launch it by 2027, with blockbuster potential exceeding $1 billion annually by the end of the decade. For Genmab, which has historically leaned on collaborations, this deal signals a clear push toward owning more of its pipeline outright.

Of course, drug development is never risk-free — trial results, regulatory hurdles, and integration bumps could all throw curveballs. But if petosemtamab delivers, Genmab has fast-tracked its move into the big leagues of oncology.

My Take  For You: Genmab isn't just buying a pipeline; it's buying speed. 

My Verdict: If you’re holding Genmab, this is a “stay the course” moment. The deal diversifiesrisk and strengthens the growth story. For new investors, patience pays: the value will take years to materialize, and you’ll want to watch those Phase 3 updates before chasing. Sensible strategy, but the payoff comes in 2027+ timelines, not next quarter.

With equity in the brand and athletes pushing viral drops, the University of Alabama is betting on more than just football wins.

This company built the tech-and got the team on board.

Check out the brand changing how college sports profits.

Gold has smashed through fresh all-time highs, and one of the clearest beneficiaries is Newmont Corporation (NYSE: NEM), the world’s largest gold miner. Shares are up more than 80% year-to-date and 4.32% in the last five days, as investors flock to safe-haven assets and mining profits expand in tandem with bullion's rally.

Newmont is uniquely positioned to capitalize on gold's renewed momentum as Wall Street worries about a government shutdown. The company has scaled production, delivered double-digit sales growth, and announced a $3 billion share buyback program, all while maintaining cost discipline in a high-margin environment. Analysts have been raising their price targets, and management has doubled down on capital returns through both buybacks and dividend payments.

My Take For You: With bullion blazing new trails, Newmont looks like a timely way to ride the gold wave.

My Verdict: For long-term investors, Newmont is a solid leveraged play on gold's strength, with the added benefits of dividends and buybacks. If you're already in, hold tight and let the gold rally do the heavy lifting. If you're new, scaling in on pullbacks makes sense, but momentum is in your favor. This is one gold stock that actually glitters.

Occidental is getting a little Wall Street buzz after reports it's exploring a sale or spin-off of its OxyChem chemical arm, with valuations floating around the $10 billion mark.

Shedding the division could streamline the business back to its oil and gas roots and unlock some hidden value for shareholders. The flip side? Spinoffs are rarely seamless.

Tesla's premarket move reflects the buildup to its quarterly delivery report. Investors are bracing for the numbers, with speculation that demand may not be as strong as in past years.

Add in the usual mix, such as shifting EV incentives, rising competition, and questions about battery supply, and you’ve got a recipe for volatility.

Lam Research received a boost after an analyst upgrade, with optimism growing around chip demand and AI-driven infrastructure spending. As one of the key equipment suppliers for semiconductor fabs, Lam sits at the heart of the supply chain.

The bullish case rests on maintaining strong orders and steady margins, which isn't always easy in a notoriously cyclical industry.

On Behalf of The FUTR Corp.

Most “next big AI” stories are still burning cash.

But not this one.

The foundation is already in place:

Now comes the real catalyst.  The rollout of consumer AI agents.

Agents that can read your bills, flag your renewals, pay your obligations, and reward you for sharing your structured, verified data.

Every bill, contract, and policy hides valuable zero-party data. A new payments backbone combined with a Utility Token unlocks it, creating a consent-driven marketplace where every transaction generates recurring revenue.

This isn’t just another startup promise. It’s a scaled, profitable engine ready to tap one of the fastest-growing markets of the decade.

And right now, the market hasn’t priced it in.

Click here to get the name and stock symbol before it does.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.